基于幽门螺杆菌耐药基因标志物的定制治疗与更高的根除成功率相关
这项回顾性研究评估了胃标本幽门螺杆菌常规抗菌药物敏感性检测及根除治疗推荐的效果。基于耐药基因标志物推荐的治疗方案与84%的根除成功率相关,且根除几率是未推荐治疗的4.4倍。这是首个描述将幽门螺杆菌基因耐药检测作为标准诊疗的研究。
要点
- 基于耐药基因标志物推荐的治疗方案根除成功率为84%。
- 推荐治疗的根除几率是未推荐治疗的4.4倍。
- 首次描述幽门螺杆菌基因耐药检测作为标准诊疗。
核心结论
- 基于耐药基因标志物推荐的治疗方案与84%的根除成功率相关,且根除几率是未推荐治疗的4.4倍。
研究设计与样本
- 回顾性研究,评估胃标本幽门螺杆菌常规抗菌药物敏感性检测及根除治疗推荐的效果。
主要发现
- 基于耐药基因标志物推荐的治疗方案根除成功率为84%。
- 推荐治疗的根除几率是未推荐治疗的4.4倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Increasing antimicrobial resistance with Helicobacter pylori infection has focused efforts to tailor eradication therapy based on identifying genetic markers of resistance to predict antimicrobial susceptibility. METHODS: In this retrospective study, we report the effect of routine inclusion of antimicrobial susceptibility testing and recommendations for eradication therapy with gastric specimens with H. pylori . RESULTS: The use of a recommended treatment regimen based on genetic markers of resistance was associated with an 84% rate of eradication success and 4.4 greater odds of eradication relative to unrecommended treatment. DISCUSSION: This is the first study describing the use of H. pylori genetic resistance testing as standard of care.
引用
- Cummings LC, Hojat LS, Nguyen DC, et al. Tailored Treatment Based on Helicobacter pylori Genetic Markers of Resistance Is Associated With Higher Eradication Success. Am J Gastroenterol. 2022. PMID: 36574274. doi:10.14309/ajg.0000000000002085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。